Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

Abstract

Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide. Although there is general agreement on the first-line use of metformin in most patients with type 2 diabetes, the ideal drug sequence after metformin failure is an area of increasing uncertainty. New treatment strategies target… (More)
DOI: 10.2147/DDDT.S37647

Topics

5 Figures and Tables

Cite this paper

@inproceedings{Capuano2013DipeptidylPI, title={Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin}, author={Annalisa Capuano and Liberata Sportiello and Maria Ida Maiorino and Francesco Rossi and Dario Giugliano and Katherine Esposito}, booktitle={Drug design, development and therapy}, year={2013} }